Evolus Inc (EOLS)
Company Info
US30052C1071
30052C107
Feb 8, 2018
Highlights
$632.51M
-$0.89
$275.02M
$186.27M
-$53.43M
$8.67 - $17.82
$23.57
13.84%
8.61
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Evolus Inc (EOLS) returned -15.40% year-to-date (YTD) and -26.11% over the past 12 months.
EOLS
-15.40%
-19.27%
-32.32%
-26.11%
-11.79%
15.37%
N/A
^GSPC (Benchmark)
0.51%
6.15%
-2.00%
12.92%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of EOLS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 26.54% | 4.44% | -17.55% | -5.24% | -18.07% | -15.40% | |||||||
| 2024 | 20.51% | 16.86% | -5.60% | -15.93% | 9.86% | -16.09% | 14.47% | 27.94% | 1.95% | 0.74% | -16.12% | -19.36% | 4.84% |
| 2023 | 38.35% | -12.70% | -6.73% | 3.31% | 3.55% | -19.67% | 37.83% | -1.30% | -7.58% | -16.85% | 24.61% | 11.19% | 40.21% |
| 2022 | 13.98% | 23.32% | 22.62% | -0.27% | 15.28% | -10.08% | 6.29% | -22.06% | -16.23% | 6.34% | -15.42% | 3.73% | 15.36% |
| 2021 | 101.19% | 79.14% | 7.27% | -29.87% | 18.77% | 16.91% | -14.47% | -2.03% | -28.11% | 2.62% | -29.16% | 17.51% | 93.75% |
| 2020 | -15.94% | -16.03% | -51.69% | 0.24% | 9.86% | 15.97% | -38.49% | 18.40% | 1.30% | -22.51% | 23.10% | -9.92% | -72.39% |
| 2019 | 37.39% | 61.71% | -14.64% | 8.02% | -44.22% | 7.50% | 21.41% | -2.87% | -9.40% | 2.11% | -12.29% | -13.01% | 2.27% |
| 2018 | 5.13% | -25.31% | -24.14% | 257.66% | 14.24% | -29.76% | 30.16% | -27.24% | -20.41% | 0.94% | -20.45% | 3.48% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of EOLS is 27, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Evolus Inc (EOLS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Evolus Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Evolus Inc was 92.41%, occurring on Oct 29, 2020. The portfolio has not yet recovered.
The current Evolus Inc drawdown is 75.73%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -92.41% | Jun 7, 2018 | 605 | Oct 29, 2020 | — | — | — |
| -45.2% | Mar 19, 2018 | 30 | Apr 30, 2018 | 9 | May 11, 2018 | 39 |
| -26.96% | May 16, 2018 | 1 | May 16, 2018 | 2 | May 18, 2018 | 3 |
| -11.07% | Feb 22, 2018 | 11 | Mar 8, 2018 | 2 | Mar 12, 2018 | 13 |
| -6.49% | May 30, 2018 | 2 | May 31, 2018 | 1 | Jun 1, 2018 | 3 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Evolus Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Evolus Inc, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -70.0%.
Valuation
The Valuation section provides an overview of how Evolus Inc is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for EOLS relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, EOLS has a P/S ratio of 2.3. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for EOLS in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, EOLS has a P/B value of 53.7. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |